Oncotarget Reports on Amazing Findings

Oncotarget is a peer-reviewed journal that is distributed around the globe. Oncotarget focuses on examining the pathological effects that both cancer and cancer treatment has on the patient. In general, they look at the impact that cancer management programs have on the patient’s perspective of life and their overall satisfaction. Oncotarget is dedicated to discussing the newest treatment options that increase hope for the patient undergoing care for their cancer. Visit Soundcloud to listen an audio podcast of Oncotarget.

Recently, Oncotarget was able to report on some hopeful findings concerning treatment for papillary thyroid carcinoma. The cancer papillary thyroid carcinoma is widely known as one of the most disheartening cancers one can develop. This is due to its reputation of resisting the most common drug used in treating the cancer, vemurafenib. The reason the cancer becomes resistant to vemurafenib is that vemurafenib seeks to repair the mutated BRAF gene that causes papillary thyroid carcinoma. The body then develops in immunity to the drug so that in no longer works.

Many patients suffering from papillary thyroid carcinoma have had their cancer go into remission only to find out that it has returned incurable due to its drug resistance.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

Dr. Carmelo Nucero recently interviewed with Oncotarget to report why papillary thyroid carcinoma may now be treated with vemurafenib and another drug called palbociclib.

Dr. Carmelo Nucero was seeking to find a way to stop the body from attacking vemurafenib. After years of research and thousands of dollars, he was able to find for the first time a combination between vemurafenib and palbociclib which allowed for therapeutic strategy to treat papillary thyroid carcinoma.

The drug palbociclib is already FDA approved and has been used in breast cancer patients for years. When vemurafenib is mixed with palbociclib, the body will spend all of its time attacking palbociclib which will allow vemurafenib to continue healing the BRAF gene.

Dr. Carmelo Nucero is hopeful that since both drugs have Artie been approved by the FDA that they will soon greenlight the ability for oncologists to use this combination to treat papillary thyroid carcinoma. Download output styles at Endnote.com

To stay up-to-date subscribe to Oncotarget’s podcast now on iTunes.